We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Higher Levels of Cystatin C in HIV/AIDS Patients with Metabolic Syndrome.
- Authors
Dragović, Gordana; Srdić, Danica; Al Musalhi, Khawla; Soldatović, Ivan; Kušić, Jovana; Jevtović, Djordje; Nair, Devaki
- Abstract
Abstract: Data about Cystatin‐C levels in HIV‐infected patients with metabolic syndrome (MetS) are still limited. Therefore, the aim of this study was to evaluate the possible correlations of serum levels of Cystatin‐C in HIV/AIDS patients treated with combined antiretroviral therapy (cART) with or without MetS. This cross‐sectional study included 89 HIV/AIDS Caucasian patients receiving cART at the HIV/AIDS Centre Belgrade, Serbia, divided into two groups according to the presence of MetS. Cystatin‐C and other biochemical parameters were measured using Cytokine‐Array‐I, Metabolic‐Array‐I and Metabolic‐Array‐II, at the Department of Clinical Biochemistry, Royal Free Hospital and University College London, UK. A linear regression model was performed to evaluate which clinical and laboratory variables had an independent effect on Cystatin‐C levels in HIV/AIDS patients. There were 33 (37%) patients with MetS and 56 (63%) without MetS. Patients with and without MetS were homogenous for age, duration of cART, number of cART combinations and CD4+ T cell count. Statistically increased Cystatin‐C levels were observed in HIV/AIDS patients with MetS (<italic>p</italic> = 0.017), when compared to patients without MetS. Data showed a positive correlation of Cystatin‐C and C‐reactive protein (<italic>r</italic> = 0.349, <italic>p</italic> = 0.001). Using linear regression modelling, significant correlations were obtained between Cystatin‐C and MetS in univariate analysis (<italic>p</italic> < 0.001). Cystatin‐C levels were significantly higher in HIV/AIDS patients with MetS <italic>versus</italic> without MetS. Early assessment of MetS using Cystatin‐C as a marker may ultimately help increase the lifespan of HIV/AIDS patients, as these patients appear to be at high risk of cardiovascular diseases.
- Subjects
CYSTATINS; HIV-positive persons; AIDS patients; METABOLIC syndrome; ANTIRETROVIRAL agents
- Publication
Basic & Clinical Pharmacology & Toxicology, 2018, Vol 122, Issue 4, p396
- ISSN
1742-7835
- Publication type
Article
- DOI
10.1111/bcpt.12919